Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Shares of Hims & Hers Health (HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded versions of Eli ...

Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.

Hims & Hers Health HIMS-6.01%decrease ... green up pointing triangle & Co. Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it aimed to bring its customers ...

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic ...

Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co.'s Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it ...

BofA keeps an Underperform rating on Hims & Hers with a $22 price target after the company indicated it is adding a branded version of Eli Lilly’s (LLY) Zepbound to its platform. The firm does ...

The selloff followed Hims & Hers’ announcement that it had added Eli Lilly’s (LLY) popular weight-loss drug Zepbound and a generic ... HIMS’ liraglutide launch will be relevant over the ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers.